Boston, September 16, 2025
News Summary
NanoViricides, Inc. will showcase its antiviral pipeline, focusing on NV-387, an advanced drug targeting respiratory viruses, at the LSX World Congress in Boston. Led by Dr. Anil R. Diwan, the presentation is crucial for engaging potential partners in the biotech sector. With promising results in animal models and preliminary clinical approval for MPox, NV-387 could significantly impact the treatment of viral infections amid rising public health concerns.
Boston
NanoViricides, Inc. will present updates on its antiviral drug pipeline and licensing opportunities at the LSX World Congress in Boston on September 17, 2025, at 12:30 PM. The presentation will take place in the LSX Biotech Showcase at the Thomas Michael Menino Convention and Exhibition Center. The company’s president and executive chairman, Dr. Anil R. Diwan, will lead the presentation and has several pre-scheduled meetings during the Congress on September 16 and 17.
Key presentation focus and clinical progress
The presentation will highlight the company’s lead candidate, NV-387, described as an ultra-broad-spectrum antiviral that targets respiratory human pathogenic viruses. NV-387 is designed to mimic sulfated proteoglycans, a common viral attachment point used by more than 90% of human viruses, and to disrupt virus particles after binding, rendering them incapable of causing infection.
NV-387 is advancing toward a Phase II Safety, Tolerability, and Efficacy Evaluation for treatment of MPox disease. The clinical protocol for this study has received preliminary approval, and NanoViricides is finalizing its clinical trial application. In lethal animal models, NV-387 has shown high effectiveness against co-circulating respiratory viruses described as the “tripledemic” (respiratory syncytial virus, Influenza A, and Coronaviruses), including reports of complete cures in RSV animal studies. The candidate has also demonstrated effectiveness in animal models for Smallpox and MPox.
Potential regulatory and market implications
If NV-387 receives regulatory approval for relevant indications, the therapy may qualify for a Priority Review Voucher (PRV), with estimated market value cited between $150 million and $350 million. Successful development for MPox could also support a potential regulatory pathway for Smallpox, which may open opportunities for government stockpiling contracts valued in the hundreds of millions of dollars. The aggregate market size for the indications targeted by NV-387 is estimated to exceed $10 billion.
Clinical and public health context
There are currently no approved antiviral drugs specifically for several of the indications noted in the company’s updates, including RSV, MPox, and Measles. The company’s materials note rising Measles cases in the USA, Canada, the UK, and Europe, underscoring ongoing public health concerns about viral respiratory and systemic infections. NV-387 is presented as a candidate that could enable “empiric therapy,” allowing clinicians to begin treatment without waiting for diagnostic test results, subject to regulatory approvals and clinical validation.
Other pipeline programs and technology platform
NanoViricides also lists additional candidates and platform capabilities. These include NV-HHV-1, a candidate targeting herpesviruses, and NV-HIV-1 for HIV. The company describes an extended nanoviricide technology designed to permit oral delivery and to provide targeted encapsulation for other drugs, suggesting potential for broader applications beyond injectable formats.
Event and networking details
The LSX World Congress runs September 16–17, 2025, and serves as a venue for life science leaders to network, explore licensing and partnering opportunities, and discuss financing and development strategies. NanoViricides’ presentation and executive meetings on September 16 and 17 are positioned to engage potential collaborators, licensors, and investors operating in the biotech and pharmaceutical sectors.
What to expect from the presentation
- Updates on NV-387 preclinical and clinical progress, including the Phase II plan for MPox.
- Details on the mechanism that targets viral attachment via sulfated proteoglycan mimicry and particle disruption.
- Summary of animal model efficacy across RSV, Influenza A, Coronaviruses, Smallpox, and MPox models.
- Information on additional candidates and the nanoviricide technology platform, including oral delivery development.
- Opportunities for licensing and follow-up meetings already scheduled during the Congress.
Background and broader implications
The company frames NV-387 as a broad antiviral approach that, if clinically validated, could change how some viral infections are treated by allowing earlier empiric therapy and addressing diseases with limited approved therapeutics. Potential regulatory incentives such as PRVs and stockpiling contracts are noted as possible commercial outcomes contingent on successful clinical development and approval. The company’s presentation at LSX is intended to communicate these scientific and commercial elements to potential partners and stakeholders.
Frequently Asked Questions
When and where will NanoViricides present at the LSX World Congress?
The company will present on September 17, 2025, at 12:30 PM in the LSX Biotech Showcase at the Thomas Michael Menino Convention and Exhibition Center in Boston, MA.
Who will deliver the presentation?
The presentation will be delivered by Dr. Anil R. Diwan, President and Executive Chairman of NanoViricides, Inc.
What is NV-387 and what diseases does it target?
NV-387 is described as an ultra-broad-spectrum antiviral that mimics sulfated proteoglycans to bind and disrupt virus particles. It targets respiratory viruses including RSV, Influenza A, Coronaviruses, and has shown activity in models for Smallpox and MPox. The company is advancing NV-387 toward Phase II evaluation for MPox.
What is the current clinical status of NV-387?
The clinical protocol for NV-387 has received preliminary approval and the company is finalizing its clinical trial application as it progresses toward a Phase II Safety, Tolerability, and Efficacy study for MPox.
What other candidates or technologies does the company have?
Other candidates include NV-HHV-1 for herpesviruses and NV-HIV-1 for HIV. The nanoviricide platform is being developed for oral delivery and targeted encapsulation of drugs.
What are the potential regulatory and market implications?
If approved, NV-387 could be eligible for a Priority Review Voucher valued between $150 million and $350 million. Success in MPox could support a Smallpox therapeutic approval and potential stockpiling contracts. The overall market for the targeted indications is estimated to exceed $10 billion.
Quick Reference Table
| Item | Details |
|---|---|
| Event | LSX World Congress 2025 — LSX Biotech Showcase |
| Presentation date & time | September 17, 2025 — 12:30 PM |
| Location | Thomas Michael Menino Convention and Exhibition Center, Boston, MA |
| Presenter | Dr. Anil R. Diwan, President and Executive Chairman |
| Lead candidate | NV-387 — ultra-broad-spectrum antiviral |
| Clinical status | Protocol preliminary approval; finalizing clinical trial application; moving toward Phase II for MPox |
| Other programs | NV-HHV-1 (herpesviruses), NV-HIV-1 (HIV); oral delivery and targeted encapsulation development |
| Potential commercial notes | Possible PRV eligibility ($150M–$350M); potential stockpiling opportunities; market estimate > $10B |
| Congress dates | September 16–17, 2025 |
Deeper Dive: News & Info About This Topic
HERE Resources
Additional Resources
- JSONline: NanoViricides to Present at LSX World Congress
- Proactive Investors: NanoViricides to Present at LSX Congress
- Wikipedia: Antiviral
- Google Search: NV-387
- Encyclopedia Britannica: Virus
Author: STAFF HERE BOSTON WRITER
BOSTON STAFF WRITER The BOSTON STAFF WRITER represents the experienced team at HEREBoston.com, your go-to source for actionable local news and information in Boston, Suffolk County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as Boston Marathon, Head of the Charles Regatta, and Boston Harborfest. Our coverage extends to key organizations like the Greater Boston Chamber of Commerce and Associated Industries of Massachusetts, plus leading businesses in finance, biotech, and insurance that power the local economy such as Fidelity Investments, Biogen, and Liberty Mutual Insurance. As part of the broader HERE network, we provide comprehensive, credible insights into Massachusetts's dynamic landscape.
